Scotland's national economic development agency operating as a non-departmental public body to foster business innovation and scale.
The Scottish laser technology specialist has raised over £1m from existing investors and Innovate UK to fund healthcare product rollouts and emissions monitoring tools.
"Designing and manufacturing state-of-the-art ultrafast infra-red lasers brings huge value and efficiencies to the global healthcare market. Our new '920' builds on a decade of research and IP development to extend our product roadmap."
The funding round was led by Puma Private Equity and will support the creation of a financial services-specific large language model.
"The financial Services industry does not need AI models that can quote Shakespeare, it needs AI models that deliver transparency, trust and above all correctness. The way to achieve this is to develop small, highly tuned language models, trained on financial services data, reviewed by financial services experts for specific financial services use cases."
NovaQuest led the financing round, which drew participation from eight investors across three continents.
"Following on from our successful seed funding round from Gabriel Investments and Equity Gap, Series A is an important milestone in our global growth plans, as we seek to improve health outcomes for animals through earlier disease diagnosis using revolutionary biomarker technology and artificial intelligence. The geographical spread of this investment round reflects the global opportunity for MI:RNA to deploy our platform for better outcomes for pets."
Gabriel Investment Syndicate and Scottish Enterprise backed the Edinburgh space firm to accelerate research and design.
"We are in the midst of the second space race with rocket developers on the cusp of launching from UK soil, with the number of launches across the globe growing exponentially."
The financing round was led by SCVC with participation from a group of institutional investors and agencies.
"Essentially, our technology generates very small droplets which are ideal for peripheral inhalation drug delivery, and also the potential for systemic drug delivery through the inhalation route rather than via injection."
-20webclip.png)